Acta Pharmaceutica Sinica B
|
2026, 16(8): 5016-5033
• Perspective •
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders
Full
Wenbo Feng1, Qingtong Zhou1, Ming-Wei Wang1,2,3,4,5
Affiliations
1 Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
2 Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China;
3 Research Center for Deepsea Bioresources, Sanya 572025, China;
4 Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmacy, Hainan Medical University, Haikou 570228, China;
5 Department of Chemistry, School of Science, The University of Tokyo, Tokyo 113-0033, Japan
doi: 10.1016/j.apsb.2026.06.035
Outline
The melanocortin-4 receptor (MC4R) is a key regulator of energy balance and a potential target for weight management. Early drug discovery endeavors were hindered by incomplete understanding of its signal transduction mechanisms and broad activation of Gs pathways. Recent advances indicate that MC4R elicits multiple intracellular responses, with Gq/₁₁ signaling in the paraventricular nucleus (PVN) neurons playing a central role in appetite suppression. High-resolution cryo-electron microscopy structures of MC4R, such as the setmelanotide-MC4R-Gq complex reported here, provide valuable insights into ligand binding, receptor activation, and biased signaling, thereby enabling the design of more selective agonists with improved safety profiles. Combination therapies targeting MC4R alongside glucagon-like peptide-1 mimetics and other agents regulating metabolic pathways have shown promise to enhance weight loss. MC4R modulators are also implicated in treating other disorders, including melanocortin signaling dysfunction. These progresses call for renewed efforts in developing the next-generation MC4R-based therapies against metabolic diseases.
MC4R
/
Biased
/
Signaling
/
Structure
/
Obesity
Wenbo Feng, Qingtong Zhou, Ming-Wei Wang.
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(8)
: 5016
-5033
.
DOI: 10.1016/j.apsb.2026.06.035
Year 2026 volume 16 Issue 8
PDF
12
5
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.06.035
- Receive Date:2025-12-05
- Online Date:2026-09-17